Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Intellia Therapeutics Inc

NTLA ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: HOLD

Last Close

$13.51

▲ +7.56%

Market Cap $1.89B · Vol 1.20M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.89B

Small Cap

Div Yield

N/A

EPS Growth

+15.97%

YoY

RSI (14)

70.22

Momentum

Beta

1.82

vs Market

52W High

$28.24

52.16% below

52W Low

$7.95

69.94% above

Volume

1.20M

Avg 1.15M

P/B

1.56

Price-to-book

ROE

-53.48%

Return on equity

Free Float

96.10%

Public shares

Shariah Compliance8 STANDARDS

✗ Intellia Therapeutics Inc (NTLA) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NTLA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+16.47%

+25.91%

+7.22%

+0.67%

YTD

+50.28%

+18.72%

-64.68%

-91.47%

Financials & Valuation

TTM · Annual

Total Revenue	$67.67M
Net Income	$-412,694,000.00
Revenue Growth (YoY)	-46.23%
Gross Margin	100.00%
Operating Margin	-651.67%
Net Profit Margin	-609.85%
ROE	-53.48%
ROA · ROIC	-40.60% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	14.40
P/B	1.56
P/FCF	N/A
EPS Growth	+15.97%
Outstanding Shares	140.13M

Technical Indicators

50-Day SMA	$13.32
200-Day SMA	$12.42
RSI (14)	70.22
Beta	1.82
52-Week High	$28.24
52-Week Low	$7.95

Volume Today	1.20M
Avg Daily Volume (30D)	1.15M
Relative Volume	1.05x
Volatility (10D)	87.31
Volatility (30D)	70.46
Free Float	96.10%

Analyst Consensus

HOLD

Current Price $13.51

Mean Target $24.80

52W Low$7.95 52W High$28.24

Current

Target

$7.95 $28.24

Current Analyst target

+83.57% upside potential · 17 analysts

Identifiers

ExchangeNasdaq

FIGIBBG007KC7PC9

ISINUS45826J1051

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.02% ONC BeOne Medicines AG +1.18% RVMD Revolution Medicines Inc -0.09% 068270.KS Celltrion Inc -2.27% ABVX Abivax SA +1.53%

Company Profile

Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.